14th October 2019

CGRP user experience survey

Have your voice heard

We are taking part in upcoming National Institute for Health and Care Excellence (NICE) and Scottish Medicine Consortium (SMC) technology appraisals for new Calcitonin Gene-Related Peptide (CGRP) medication.

These processes will be used to assess if the medication can be available on the NHS to treat migraine.

If you have or are taking CGRP medication to treat migraine, we would welcome you sharing your experience with us in our CGRP survey. This will ensure that your voice is heard and help strengthen the overall patient voice in the process.

The survey should only take about 10-15 minutes to complete. You can find out more about it and take it here.